Evidence map›Paper›PMID 32524995›Full record

ArticleBiochemical pharmacology2020

Pharmacological activity and NMR solution structure of the leech peptide HSTX-I.

Kirsten L McMahon, Bryan Tay, Jennifer R Deuis, Brian S Tanaka, Steve Peigneur, Ai-Hua Jin, Jan Tytgat, Stephen G Waxman, Sulayman D Dib-Hajj, Irina Vetter and 1 more

Open access · greenAbstract read
In one paragraph

Article in Biochemical pharmacology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.5field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 6 citations in OpenAlex.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 5 institutions in 3 countries.

Kirsten L McMahonInstitute for Molecular Bioscience, The University of Queensland, Brisbane, Queensland 4072, Australia.
Bryan TayInstitute for Molecular Bioscience, The University of Queensland, Brisbane, Queensland 4072, Australia.
Jennifer R DeuisInstitute for Molecular Bioscience, The University of Queensland, Brisbane, Queensland 4072, Australia.
Brian S TanakaCenter for Neuroscience and Regeneration Research, New Haven, CT, United States; Department of Neurology, Yale University School of Medicine, New Haven, CT, United States; Rehabilitation Research Center, Veterans Affairs Connecticut Healthcare System, West Haven, CT, United States.
Steve PeigneurToxicology and Pharmacology, Katholieke Universiteit (KU) Leuven, Campus Gasthuisberg, Leuven, Belgium.
Ai-Hua JinInstitute for Molecular Bioscience, The University of Queensland, Brisbane, Queensland 4072, Australia.
Jan TytgatToxicology and Pharmacology, Katholieke Universiteit (KU) Leuven, Campus Gasthuisberg, Leuven, Belgium.
Stephen G WaxmanCenter for Neuroscience and Regeneration Research, New Haven, CT, United States; Department of Neurology, Yale University School of Medicine, New Haven, CT, United States; Rehabilitation Research Center, Veterans Affairs Connecticut Healthcare System, West Haven, CT, United States.
Sulayman D Dib-HajjCenter for Neuroscience and Regeneration Research, New Haven, CT, United States; Department of Neurology, Yale University School of Medicine, New Haven, CT, United States; Rehabilitation Research Center, Veterans Affairs Connecticut Healthcare System, West Haven, CT, United States.
Irina VetterInstitute for Molecular Bioscience, The University of Queensland, Brisbane, Queensland 4072, Australia; School of Pharmacy, The University of Queensland, Woolloongabba, Queensland 4103, Australia. Electronic address: i.vetter@imb.uq.edu.au.
Christina I SchroederInstitute for Molecular Bioscience, The University of Queensland, Brisbane, Queensland 4072, Australia; National Cancer Institute, National Institutes of Health, Frederick, MD 21702, United States. Electronic address: christina.schroeder@nih.gov.
University of Queensland · AUCenter for Neuroscience and Regenerative Medicine · USKU Leuven · BENational Cancer Institute · USVA Connecticut Healthcare System · US

Funding

Discovery and development of voltage-gated sodium channel inhibitorsZIABC012003 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI SCHROEDER, INGRID · 2020 to 2022
$291k
Intramural NIH HHS Z99 CA999999
6 · The paper itself

Abstract

The role of voltage-gated sodium (Na

Indexed as

Amino Acid SequenceAnalgesicsAnimalsCells, CulturedHumansHyperalgesiaLeechesMagnetic Resonance SpectroscopyMice, Inbred C57BLMice, KnockoutNeuronsPatch-Clamp TechniquesPeptidesRats, Sprague-DawleySodium Channel BlockersSolutionsAnalgesicsPeptidesSodium Channel BlockersSolutionsToxins, BiologicalVoltage-Gated Sodium ChannelsChronic painElectrophysiologyLeechNMRVoltage-gated sodium channels

Identifiers

PMID32524995
PMCPMC8494138
OpenAlexW3033894917

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.